Newsroom

CV6 Therapeutics Named Innovative Company of the Year at the 2026 AIB Business Eye Awards

CV6 Therapeutics Named Innovative Company of the Year at the 2026 AIB Business Eye Awards

The award recognizes CV6’s first-in-class therapeutic programs, while Founder and CEO Dr. Robert D. Ladner also received Highly Commended recognition for Business Personality of the Year.

CV6 Therapeutics Named Team of the Year at Belfast Chamber Business Awards

CV6 Therapeutics Named Team of the Year at Belfast Chamber Business Awards

At the Belfast Chamber Business Awards, held in partnership with Bank of Ireland, CV6 won Team of the Year, sponsored by Cathedral Quarter BID, Belfast, and received Highly Commended recognition for CV6-168 in Business Innovation, sponsored by Kingsbridge Healthcare Group.

CV6 Therapeutics Founder Shortlisted for Business Post CEO of the Year Award

CV6 Therapeutics Founder Shortlisted for Business Post CEO of the Year Award

Dr. Robert D. Ladner has been shortlisted alongside nine business leaders from across the island of Ireland after building CV6 into a GUSR platform company whose first-in-class lead oncology candidate is advancing through a first-in-human Phase 1a clinical trial.

AIB Business Eye Award Nominations Recognise CV6 Innovation, Growth and Leadership

AIB Business Eye Award Nominations Recognise CV6 Innovation, Growth and Leadership

Organized by Northern Ireland business magazine Business Eye in partnership with AIB, the awards are marking their 20th year of recognizing achievement, innovation and leadership across the region’s business community.

HIRANI Spotlights CV6’s Belfast Biotechnology Story

HIRANI Spotlights CV6’s Belfast Biotechnology Story

From Discovery to Clinical Development: CV6 grew from an original scientific idea into a clinical-stage biotechnology company, the Northern Ireland ecosystem supporting that journey, and the company’s work across cancer and inflammatory disease.

BBC Radio Foyle Interview with CV6 CEO and Founder

BBC Radio Foyle Interview with CV6 CEO and Founder

Dr. Robert Ladner joins Mark Patterson in the studio, to discuss his work to improve outcomes for cancer patients and what has brought him to the place of his roots, the Northwest.

Archive

CV6 Named Finalist in Two Belfast Chamber Business Awards in Partnership With Bank of Ireland

QUBIS Features Bob Ladner on Building CV6 in Belfast

Op-Ed: Science Is Not a Medicine. Why Northern Ireland was the right place to build CV6 Therapeutics

CV6 Therapeutics Appoints Dr. Chris Takimoto to Board of Directors

CV6 Therapeutics Contributes to Discussions on the Future of Oncology Innovation Across Ireland

CV6 Therapeutics Joins QUBIS “Spin Out to Stand Out” Event at Queen’s University Belfast

Drug Discovery World Reports on CV6-168 Entering Clinical Trials

CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial

CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

CV6 Therapeutics to Attend JP Morgan Week

CV6 Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial

CV6 CEO Co-authors Study on Cancer Care in Ireland

BioTech Nation Podcast: Old Dog, New Tricks ???

CV6 CEO Presents at ‘Agreement 25: Cancer Knows no Borders’

Fierce Pharma’s Spotlight on CV6 and Northern Ireland Life Sciences

UTV Reports on CV6-168’s Progress Toward First Human Trials

CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial

FirstWord Pharma Publishes CV6’s Clinical Development Funding Announcement

News Letter Highlights Invest NI’s Support for CV6’s Cancer Research

The Irish Times Reports on CV6’s Cancer Drug Development

CV6 Therapeutics Featured in the NI Edition of the 12 Clusters of Tech

CV6 Therapeutics Inc Recognised as a Platinum Level Innovator

CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event